NCT03827200View on ClinicalTrials.gov

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

December 29, 2020

Study Completion Date

January 21, 2021

Conditions
CirrhosisPortal HypertensionAscites
Interventions
DRUG

Ambrisentan

Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.

Trial Locations (6)

28007

Hospital Universitario Gregorio Marañón, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28222

Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda

08036

Hospital Clinic Barcelona, Barcelona

08035

Vall d'Hebron University Hospital, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors
All Listed Sponsors
lead

Noorik Biopharmaceuticals AG

INDUSTRY